Pfizer stops late-stage mild heart failure trial early on positive data
This article was originally published in Scrip
Executive Summary
Pfizer's Inspra (eplerenone) has met its primary endpoint in patients with mild chronic systolic heart failure and left ventricular systolic dysfunction, show interim results from the Phase IIIb EMPHASIS-HF trial, prompting the company to halt the trial. The company is now seeking an amendment to the trial's protocol so that can continue to dose patients in an open-label six-month extension phase of the trial.